Chemotherapy-induced Nausea and Vomiting Clinical Trial
The purpose of this study is to clarify whether distal-proximal point association is more effective than partial match point association by electro-acupuncture in the management of chemotherapy-induced nausea and vomiting .
Status | Not yet recruiting |
Enrollment | 240 |
Est. completion date | September 2016 |
Est. primary completion date | June 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: 1. Be diagnosed as cancer and need to accept chemotherapy. 2. The score of Karnofsky =70 3. Patients of either gender and older than 18 years 4. Patients receiving chemotherapy both outpatients and inpatients 5. Patients receiving chemotherapy either the first or multiple cycle, but the patient will be taken in only one time 6. To receive chemotherapy containing cisplatin(DDP=75mg/m2) or joint chemotherapy programmes of Anthracyclines(Adriamycin=40mg/m2 or epirubicin=60mg/m2) 7. Life expectancy= 6 months 8. Willing to participate in the study and be randomized into one of the four study groups. Exclusion Criteria: 1. To receive radiotherapy and chemotherapy 2. Gastrointestinal tumors 3. Patients with serious liver disease or abnormal hepatorenal function (AST,ACT, and TBIL are 3 times more than normal, BUN and Cr are 2 times more than normal) 4. Presence of cardiac pacemaker 5. Active skin infection 6. Nausea and/or vomiting resulting from opioids or metabolic imbalance (electrolyte disturbances) 7. Patients unable to provide self-care or communication 8. Nausea and/or vomiting resulting from mechanical risk factors (i.e., intestinal obstruction) 9. Brain metastases 10. Women in pregnant and lactating period |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | Tianjin University of TCM | Tianjin | Tianjin |
Lead Sponsor | Collaborator |
---|---|
Tianjin University of Traditional Chinese Medicine | National Basic Research Program of China |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | the number of blood cells | the number of WBC,RBC,hemoglobin,PLT,the percents of GRA,LYM | 3 weeks | Yes |
Other | cardial electrical activity | 3 weeks | Yes | |
Other | hepatic function | The Outcome Measures will be assessed by blood, the metrics of ALT,AST,TBIL is IU/L,IU/L,and µmol/L. | 3 weeks | Yes |
Other | other adverse effect during the chemotherapy | 3 weeks | Yes | |
Other | renal function | The Outcome Measures will be assessed by blood, the metrics of BUN,Scr is mmol/L and µmol/L. | 3 weeks | Yes |
Primary | the frequency of Nausea and Vomiting | 3 weeks | No | |
Primary | the extent of Nausea and Vomiting | 3 weeks | No | |
Primary | Rhodes Index of Nausea, Vomiting and Retching | 3 weeks | No | |
Secondary | the condition of constipation and diarrhea | 3 weeks | Yes | |
Secondary | gastric electrical activity (electrogastrogram) | 3 weeks | No | |
Secondary | the life quality of the patients | 3 weeks | No | |
Secondary | the Anxiety and Depression of the patients | 3 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04054193 -
Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)
|
Phase 4 | |
Recruiting |
NCT04430361 -
the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy
|
Phase 2 | |
Recruiting |
NCT03668639 -
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
|
Phase 2/Phase 3 | |
Completed |
NCT02285647 -
An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant
|
Phase 1 | |
Terminated |
NCT01874119 -
Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT01757210 -
A Study to Evaluate the Safety and Efficacy of Aprepitant (MK0869) for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients
|
N/A | |
Completed |
NCT01442376 -
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
|
Phase 3 | |
Withdrawn |
NCT00891761 -
A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
|
Phase 3 | |
Completed |
NCT01031498 -
Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting
|
Phase 2 | |
Terminated |
NCT02519842 -
Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)
|
Phase 3 | |
Recruiting |
NCT03232541 -
The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and Vomiting
|
N/A | |
Completed |
NCT02909478 -
Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer
|
Phase 3 | |
Terminated |
NCT03237611 -
Low Dose Aprepitant for Patients Receiving Carboplatin
|
Phase 2 | |
Completed |
NCT03649230 -
Observational Study on the Use of Akynzeo® in Patients Receiving HEC
|
||
Not yet recruiting |
NCT02933099 -
Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting
|
Phase 3 | |
Completed |
NCT02557035 -
An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting
|
Phase 3 | |
Completed |
NCT00787566 -
Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting
|
Phase 2 | |
Completed |
NCT06121414 -
Effectiveness of Laserpuncture and Standard Antiemetic on RINVR Scores in Adolescent Patients Undergoing Chemotherapy
|
N/A | |
Completed |
NCT04918069 -
Capsaicin to Prevent Delayed Chemotherapy Induced Nausea and Vomiting (CapCIN)
|
Phase 2 | |
Completed |
NCT05851625 -
Efficacy of Ear Acupuncture in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients
|
N/A |